Britton H, et al. - In a retrospective cohort of women with endometrial carcinomas (ECs) <50 years old at diagnosis, researchers assessed the prognostic value of Proactive Molecular risk classifier for Endometrial Carcinoma (ProMisE). They applied this tool to the study population and examined clinicopathological parameters in relation to four ProMisE molecular subtypes (MMR deficient, POLE mutated, p53 wild type, and p53 abnormal). Other than the presence of synchronous ovarian tumors and fertility, an association of ProMisE subtypes with differences in all measured clinicopathological parameters was observed. They found strong associations of ProMisE subtypes with outcomes (overall, disease-specific, and progression-free survival). They concluded that in young women with EC, ProMisE molecular classification has prognostic value and it allowed early stratification and risk assignment to direct care.